These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21969317)

  • 1. Reversal of new oral anticoagulants.
    Battinelli EM
    Circulation; 2011 Oct; 124(14):1508-10. PubMed ID: 21969317
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter by Marlu et al regarding article, "reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects".
    Marlu R; Hodaj E; Pernod G
    Circulation; 2012 Apr; 125(16):e615; author reply e616. PubMed ID: 22529073
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter by Bernstein et al regarding article, "reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Bernstein RA; Alberts MJ; Garcia DA
    Circulation; 2012 Apr; 125(16):e614; author reply e616. PubMed ID: 22529072
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
    Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of an antagonist to reverse the action of dabigatran.
    Jolobe OM
    QJM; 2012 Feb; 105(2):212-4. PubMed ID: 22052956
    [No Abstract]   [Full Text] [Related]  

  • 6. Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
    Moorman ML; Nash JE; Stabi KL
    J Trauma Acute Care Surg; 2014 Sep; 77(3):486-94; quiz 486-94. PubMed ID: 25159255
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing new oral anticoagulants in the intensive care unit.
    Gass JA; Weeks PA
    Crit Care Nurs Q; 2013; 36(4):390-9. PubMed ID: 24002428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M; Hjemdahl P; Holmström M; Ivert T
    Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract]   [Full Text] [Related]  

  • 10. Laboratory testing for the new oral anticoagulants: a review of current practice.
    Favaloro EJ; Bonar R; Butler J; Marsden K
    Pathology; 2013 Jun; 45(4):435-7. PubMed ID: 23635821
    [No Abstract]   [Full Text] [Related]  

  • 11. Bleeding and the new anticoagulants: strategies and concerns.
    Samama CM; Levy JH
    Anesthesiology; 2015 Feb; 122(2):236-7. PubMed ID: 25437499
    [No Abstract]   [Full Text] [Related]  

  • 12. Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.
    Levi M
    Thromb Haemost; 2012 Aug; 108(2):201-2. PubMed ID: 22739774
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
    Baglin T; Keeling D; Kitchen S;
    Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
    Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
    Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcome after a subdural hematoma treated with feiba in a 77-year-old patient treated by rivaroxaban.
    Maurice-Szamburski A; Graillon T; Bruder N
    J Neurosurg Anesthesiol; 2014 Apr; 26(2):183. PubMed ID: 24296541
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
    Herrmann R; Thom J; Wood A; Phillips M; Muhammad S; Baker R
    Thromb Haemost; 2014 May; 111(5):989-95. PubMed ID: 24352511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
    Grottke O; van Ryn J; Spronk HM; Rossaint R
    Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.